Drugmakers have their sights set on a class of cancer drugs known as antibody drug conjugates, or ADCs, to drive growth, CNBC reported Jan. 14.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
Drugmakers turn to class of cancer drugs to fuel growth in 2024
